OUTLOOK THERAPEUTICS, INC.

Analyst Reco. Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Real-time Estimate Cboe BZX Other stock markets 09:44:59 2024-06-05 am EDT			5-day change	1st Jan Change
7.11 ^USD	-1.11%		-9.26%	-8.63%

May. 28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
May. 28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	Mar. 27	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	Feb. 15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	Feb. 15	MT
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	Jan. 25	MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	Jan. 25	MT
Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target	Dec. 27	MT
Chardan Downgrades Outlook Therapeutics to Neutral From Buy	23-08-31	MT
HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1	23-08-31	MT
Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy	23-08-30	MT
Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50	23-08-30	MT
BTIG Downgrades Outlook Therapeutics to Neutral From Buy	23-08-30	MT
Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target	23-07-13	MT
Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target	23-04-03	MT
Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target	23-02-06	MT
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating	23-01-06	MT
BTIG Starts Outlook Therapeutics at Buy With $7 Price Target	22-10-31	MT
Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target	22-09-13	MT
Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating	21-12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer